← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Methylhydrazines
procarbazine
L01XB01
Adult Dosing
- Hodgkin lymphoma (combination therapy): 2 to 4 mg/kg/day orally in single or divided doses for 7 to 14 days
- MOPP regimen: 100 mg/m^2/day orally on days 1 through 14 of a 28-day cycle
Pediatric Dosing
- Hodgkin lymphoma (children >= 1 year): 50 mg/m^2/day orally adjusted based on tolerance and blood counts, or 100 mg/m^2/day in combination regimens
Indications
- Hodgkin lymphoma (as part of MOPP and other combination regimens)
- Brain tumors (gliomas, glioblastoma multiforme, as second-line therapy)
Mechanism of Action
- Methylhydrazine derivative acting as an alkylating antineoplastic agent
- Inhibits DNA, RNA, and protein synthesis via alkylation and generation of hydrogen peroxide
Contraindications
- Hypersensitivity to procarbazine
- Severe bone marrow suppression
- Severe hepatic or renal impairment
- Concurrent use of tricyclic antidepressants, sympathomimetics, MAO inhibitors, and tyramine-rich foods
Adverse Reactions
- Myelosuppression (leukopenia, thrombocytopenia, anemia)
- Nausea, vomiting, anorexia
- Central nervous system toxicity (somnolence, neuropathy, confusion, hallucinations)
- Secondary malignancies (acute leukemias)
- Gonadal dysfunction (azoospermia, amenorrhea)
- Disulfiram-like reaction with alcohol
Drug Interactions
- MAO inhibitors and tricyclic antidepressants (risk of hypertensive crisis, hyperpyrexia)
- Sympathomimetics, antihistamines, and CNS depressants (potentiation of effects)
- Ethanol (disulfiram-like flushing, vomiting, tachycardia)
- Tyramine-rich foods (hypertensive crisis due to weak MAO inhibition)
Curated Content: Needs Vetting Before Put to Clinical Use